NCT04875676View on ClinicalTrials.gov

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

October 30, 2021

Study Completion Date

February 16, 2022

Conditions
Norovirus Infections
Interventions
BIOLOGICAL

VXA-G1.1-NN

Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant

Trial Locations (1)

90630

WCCT Global, Inc., Cypress

Sponsors

Lead Sponsor

Vaxart
All Listed Sponsors
lead

Vaxart

INDUSTRY

NCT04875676 - Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines | Biotech Hunter | Biotech Hunter